AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio cash
Cash and short-term investments held at the end of each period.
AnaptysBio's cash was $164.14M at Jun 30, 2026. For fiscal 2025 it was $211.64M, down 25.8% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $548.10M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $211.64M | -25.8% |
| FY2024 | Dec 31, 2024 | $285.37M | -19.6% |
| FY2023 | Dec 31, 2023 | $354.94M | -19.6% |
| FY2022 | Dec 31, 2022 | $441.24M | -19.5% |
| FY2021 | Dec 31, 2021 | $548.10M | +39.2% |
| FY2020 | Dec 31, 2020 | $393.71M | +5.2% |
| FY2019 | Dec 31, 2019 | $374.29M | -12.4% |
| FY2018 | Dec 31, 2018 | $427.14M | +71.9% |
| FY2017 | Dec 31, 2017 | $248.47M | +384.4% |
| FY2016 | Dec 31, 2016 | $51.29M | -0.9% |
| FY2015 | Dec 31, 2015 | $51.74M | +132.3% |
| FY2014 | Dec 31, 2014 | $22.27M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $164.14M | -25.9% |
| Q1 FY2026 | Mar 31, 2026 | $286.46M | -15.7% |
| Q4 FY2025 | Dec 31, 2025 | $211.64M | -25.8% |
| Q3 FY2025 | Sep 30, 2025 | $248.96M | -42.1% |
| Q2 FY2025 | Jun 30, 2025 | $221.41M | -36.9% |
| Q1 FY2025 | Mar 31, 2025 | $339.94M | -4.2% |
| Q4 FY2024 | Dec 31, 2024 | $285.37M | -19.6% |
| Q3 FY2024 | Sep 30, 2024 | $430.12M | +4.1% |
| Q2 FY2024 | Jun 30, 2024 | $350.80M | -18.3% |
| Q1 FY2024 | Mar 31, 2024 | $354.67M | -17.7% |
| Q4 FY2023 | Dec 31, 2023 | $354.94M | -19.6% |
| Q3 FY2023 | Sep 30, 2023 | $413.05M | -6.8% |
| Q2 FY2023 | Jun 30, 2023 | $429.49M | -2.9% |
| Q1 FY2023 | Mar 31, 2023 | $431.15M | -14.7% |
| Q4 FY2022 | Dec 31, 2022 | $441.24M | -19.5% |
| Q3 FY2022 | Sep 30, 2022 | $442.97M | +18.4% |
| Q2 FY2022 | Jun 30, 2022 | $442.15M | +13.1% |
| Q1 FY2022 | Mar 31, 2022 | $505.62M | +32.9% |
| Q4 FY2021 | Dec 31, 2021 | $548.10M | +39.2% |
| Q3 FY2021 | Sep 30, 2021 | $374.12M | +10.6% |
| Q2 FY2021 | Jun 30, 2021 | $390.91M | +3.4% |
| Q1 FY2021 | Mar 31, 2021 | $380.42M | +4.9% |
| Q4 FY2020 | Dec 31, 2020 | $393.71M | +5.2% |
| Q3 FY2020 | Sep 30, 2020 | $338.41M | -19.6% |
| Q2 FY2020 | Jun 30, 2020 | $377.94M | -10.5% |
| Q1 FY2020 | Mar 31, 2020 | $362.54M | -12.8% |
| Q4 FY2019 | Dec 31, 2019 | $374.29M | -12.4% |
| Q3 FY2019 | Sep 30, 2019 | $421.06M | -14.7% |
| Q2 FY2019 | Jun 30, 2019 | $422.28M | +57.6% |
| Q1 FY2019 | Mar 31, 2019 | $415.73M | +67.5% |
| Q4 FY2018 | Dec 31, 2018 | $427.14M | +71.9% |
| Q3 FY2018 | Sep 30, 2018 | $493.87M | +326.6% |
| Q2 FY2018 | Jun 30, 2018 | $267.97M | +151.8% |
| Q1 FY2018 | Mar 31, 2018 | $248.23M | +139.7% |
| Q4 FY2017 | Dec 31, 2017 | $248.47M | +384.4% |
| Q3 FY2017 | Sep 30, 2017 | $115.78M | +145.3% |
| Q2 FY2017 | Jun 30, 2017 | $106.42M | – |
| Q1 FY2017 | Mar 31, 2017 | $103.56M | – |
| Q4 FY2016 | Dec 31, 2016 | $51.29M | – |
| Q3 FY2016 | Sep 30, 2016 | $47.19M | – |
See a number that looks wrong?